[1] Nafakhi H, Al-Mosawi A, Al-Nafakh H, et al. Association of pericardial fat volume with coronary atherosclerotic disease assessed by CT angiography. Br J Radiol, 2014, 87(1038):20130713. [2] Hu X, Tong H. Dynamic and conventional electrocardiograms for diagnosing arrhythmic coronary atherosclerotic heart disease: a comparative analysis. Am J Transl Res, 2021, 13(5):5697-5701. [3] Wong MC, Zhang DX, Wang HH. Rapid emergence of atherosclerosis in Asia: a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies. Curr Opin Lipido, 2015, 26(4):257-269. [4] Zheng J, Huang M, Huang Q, et al. The relationship between fetuin-A and coronary atherosclerotic heart disease (CHD) and CHD-related risk factors: A retrospective study. Medicine (Baltimore), 2021, 100(43):e27481. [5] Ades PA, Savage PD. Obesity in coronary heart disease: An unaddressed behavioral risk factor. Prev Med, 2017, 104:117-119. [6] Shakiba M, Mansournia MA, Salari A, et al. Accounting for time-varying confounding in the relationship between obesity and coronary heart disease: analysis with G-estimation: The ARIC Study. Am J Epidemiol, 2018, 187(6):1319-1326. [7] Chen LZ, Jing XB, Wu CF, et al. Nonalcoholic fatty liver disease-associated liver fibrosis is linked with the severity of coronary artery disease mediated by systemic inflammation. Dis Markers, 2021, 2021:6591784. [8] Kopiczko N, Bobrus-Chociej A, Harasim-Symbor E, et al. Serum concentration of fatty acids in children with obesity and nonalcoholic fatty liver disease. Nutrition, 2021, 94:111541. [9] Wang P, Qiang H, Song Y, et al. Association between nonalcoholic fatty liver and Gensini score in patients with coronary heart disease: a cross-sectional study. Cardiology, 2019, 144(3-4):90-96. [10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华糖尿病杂志, 2010, 2(1): 15-19. [11] Liao R, Fu YP, Wang T, et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:a retrospective cohort study at two centers in China. Oncotarget, 2017, 8(1): 1774-1781. [12] Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020, 69(9):1691-1705. [13] Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol, 2014, 20(7):1724-1745. [14] Peppes V, Rammos G, Manios E, et al. Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: a hospital-based, prospective study in Greek patients. Clin Interv Aging, 2008, 3(4):699-710. [15] Cazzo E, Jimenez LS, Pareja JC, et al. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg, 2015, 25(6):982-985. |